作者
Kathleen M Andersen, Benjamin A Bates, Emaan S Rashidi, Amy L Olex, Roslyn B Mannon, Rena C Patel, Jasvinder Singh, Jing Sun, Paul G Auwaerter, Derek K Ng, Jodi B Segal, Brian T Garibaldi, Hemalkumar B Mehta, G Caleb Alexander, Melissa A Haendel, Christopher G Chute
发表日期
2022/1/1
期刊
The Lancet Rheumatology
卷号
4
期号
1
页码范围
e33-e41
出版商
Elsevier
简介
Background
Many individuals take long-term immunosuppressive medications. We evaluated whether these individuals have worse outcomes when hospitalised with COVID-19 compared with non-immunosuppressed individuals.
Methods
We conducted a retrospective cohort study using data from the National COVID Cohort Collaborative (N3C), the largest longitudinal electronic health record repository of patients in hospital with confirmed or suspected COVID-19 in the USA, between Jan 1, 2020, and June 11, 2021, within 42 health systems. We compared adults with immunosuppressive medications used before admission to adults without long-term immunosuppression. We considered immunosuppression overall, as well as by 15 classes of medication and three broad indications for immunosuppressive medicines. We used Fine and Gray's proportional subdistribution hazards models to estimate the hazard ratio …
学术搜索中的文章
KM Andersen, BA Bates, ES Rashidi, AL Olex… - The Lancet Rheumatology, 2022